Hey guys I just wanted to create a thread discussing some of the differences between Ryoncil and Jakafi trial results prior to approval/rejection from the fda. From what I understand Novartis did a single arm trial with only a small number of patients prior to approval due to it demonstrating approx 69% overall response rate vs around 30% in the standard care group however there were significant adverse events such as thrombocytopenia, anaemia and cytomegalovirus etc. I get that Jakafi was already approved for other conditions and has a defined MOA but how can you turn down Ryoncil and not Jakafi with their relative safety profiles. Why can’t mesoblast perform a retrospective study on their patients in Japan and use that to support efficacy etc
- Forums
- ASX - By Stock
- Ruxolitinib vs Ryoncil
Hey guys I just wanted to create a thread discussing some of the...
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
97.0¢ |
Change
0.030(3.19%) |
Mkt cap ! $1.110B |
Open | High | Low | Value | Volume |
94.0¢ | 98.0¢ | 92.0¢ | $3.113M | 3.242M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
35 | 95531 | 97.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.5¢ | 190778 | 24 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
39 | 132508 | 0.970 |
16 | 202733 | 0.965 |
15 | 201222 | 0.960 |
11 | 254207 | 0.955 |
10 | 779652 | 0.950 |
Price($) | Vol. | No. |
---|---|---|
0.975 | 183027 | 29 |
0.980 | 149590 | 22 |
0.985 | 90223 | 14 |
0.990 | 75752 | 6 |
0.995 | 68179 | 4 |
Last trade - 15.48pm 03/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
TON
TRITON MINERALS LTD
Adrian Costello, Executive Director
Adrian Costello
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online